StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals EYLEA HD U.S. Net Product Sales YoY Growth by Quarter

EYLEA HD U.S. Net Product Sales YoY Growth (%) (%)

Regeneron Pharmaceuticals EYLEA HD U.S. Net Product Sales YoY Growth: 62.0% in Q3 2026, up 52.0 pts from a year earlier.

Latest, Q3 2026
62.0%
Period ended Sep 30, 2026
Change on a year earlier
+52.0 pts
10.0% in Q3 2025
History
9 quarters
Since Q4 2023
Sources
9
Documents cited below

Where the Q3 2026 figure comes from

“Release Narrative Revenues (FY2026Q3): EYLEA HD - U.S. | $ | 699 | $ | 431 | 62 | %”

Source: Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗

Reported in Form 8-K (EX-99.1) Financial Results — Revenues Narrative Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEYLEA HD U.S. Net Product Sales YoY Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 202662.0%+52.0 ptsForm 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 202652.0%+23.0 ptsForm 8-K (exhibit991q22026.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 202652.0%-2.0 ptsForm 8-K (exhibit991q12026.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202566.0%-82.0 ptsForm 8-K (exhibit991q42025.htm, filed 2026-01-30) ↗
Q3 2025Sep 30, 202510.0%–Form 8-K (exhibit991q32025.htm, filed 2025-10-28) ↗
Q2 2025Jun 30, 202529.0%–Form 8-K (exhibit991q22025.htm, filed 2025-08-01) ↗
Q1 2025Mar 31, 202554.0%–Form 8-K (exhibit991q12025.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 2024148.0%-18.0 ptsForm 8-K (exhibit991q42024.htm, filed 2025-02-04) ↗
Q4 2023Dec 31, 2023166.0%–Form 8-K (exhibit991q42023.htm, filed 2024-02-02) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals EYLEA HD U.S. Net Product Sales YoY Growth (%), quarterly Q4 2023–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-eylea-hd-us-yoy

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?